Latest News

Salesforce's 18% net margin and fortress balance sheet contrast sharply with ServiceNow's 21% revenue growth and AI-driven momentum, a classic growth-versus-value showdown.

Dividend stocks are getting hit by rising rates, but this trio of high-yielders is still worth buying and holding.

Both companies burn cash and carry heavy debt, but are chasing huge market potential for their services.

We'll know for sure in just a few days.

What's bad for bond investors doesn't have to be bad for stocks.

Eli Lilly isn't content with the success of its current GLP-1 drugs; it's on the hunt for even better weight loss solutions.

Hyperscalers like Google are shifting AI data center buildouts to Finland and Norway, drawn by surplus power, stable grids, clear permitting and local support.

Accenture, Curtiss-Wright, and Starbucks all raised their dividends, with Starbucks' hike coming amid reports it explored acquiring Chipotle during its ongoing turnaround.

There's always more to the matter than mere yield (although dividend yields are still important).

This under-the-radar enterprise software stock boasts a Superscore of 83 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

Chewy trades at a fraction of Coupang's valuation multiple, but one faces Amazon's shadow while the other grapples with regulatory headwinds and a major data breach.

SpaceX's recent Starship launch marked a milestone for the company, as it was its first one that successfully went into orbit.

Royal Caribbean's $3 billion Sandals resort stake has driven shares up amid analyst optimism, though debt and fuel costs pose risks as the cruise business remains strong heading into 2027.

Every investor should have exposure to energy, but with oil prices high, you need to be selective if you are looking for reliable dividends.

Bristol Myers Squibb scored two Phase 3 wins on Monday in lung disease and cancer. The stock rose, while a key rival plunged.

Amazon stock was flat following reports it is in talks to acquire AI startup Decart for $7 billion.

First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged.

The S&P 500 is trading at historical valuations, making some investors nervous a stock market crash is on the way.

The front-runner of the nascent eVTOL industry could mint new millionaires.

Facing prediction-market pressure, Flutter, Las Vegas Sands, and Penn Entertainment took different promotion strategies in 2026, with mixed stock results and only Penn's marketing pullback gaining investor favor.

Major index funds are heavily concentrated with the same few tech names. How can investors avoid overlapping stocks?

Oppenheimer raised Viking Therapeutics' price target to $120, citing strong trial data, and an improving probability of success for its key drug.